Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating pharmacokinetics, efficacy and safety of subcutaneous CT-P13 as induction therapy in adults with active Crohn's disease or ulc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• CT-P13 Subcutaneous (infliximab biosimilar)

Snippet

Sponsor: CMC Ambroise Paré | Conditions: Inflammatory Bowel Diseases | Phase 3 | Status: UNKNOWN